Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO(R) (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) in May 2022 NEWTON, Mass. and FLORENCE, Italy,... Biopharmaceuticals, Oncology, Regulatory Karyopharm Therapeutics, Menarini Group, NEXPOVIO , selinexor, multiple myeloma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news